LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR)

Category Primary study
JournalJournal of Clinical Oncology
Year 2011
This article has no abstract
Epistemonikos ID: f088c1b905178b9eaa024e95bf12813e73290e67
First added on: Feb 04, 2025